Philips North America vs ZHEJIANG JUTAI PHARM: FDA Enforcement Comparison

Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for ZHEJIANG JUTAI PHARM.

Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.

ZHEJIANG JUTAI PHARM: 0 warning letters, 0 recalls, 1 approval record, 0 Form 483s.

Side by side

Philips North America — Warning letters0

ZHEJIANG JUTAI PHARM — Warning letters0

Philips North America — Recalls355

ZHEJIANG JUTAI PHARM — Recalls0

Philips North America — Approval records0

ZHEJIANG JUTAI PHARM — Approval records1

Philips North America — Form 483s0

ZHEJIANG JUTAI PHARM — Form 483s0

Timeline

Philips North America

Most recent FDA action: July 1, 2026

Full history →

ZHEJIANG JUTAI PHARM

Most recent FDA action: September 8, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"Philips North America vs ZHEJIANG JUTAI PHARM: FDA Enforcement Comparison." Argus HQ, accessed September 11, 2026. https://argushq.ai/compare/philips-north-america-vs-zhejiang-jutai-pharm

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗